Non-invasive Ventilation vs Oxygen Therapy After Extubation Failure
Launched by FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA · Feb 4, 2019
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
Patients. Medical and surgical patients admitted to intensive care unit with 18 years of age or older in weaning from their first episode of mechanical ventilation for more than 24 hours were included. Patients with structural neurological disorder, acute toxic-metabolic neurological encephalopathy with neurological deficit \[estimated by a Glasgow Coma Score \<14 points\] at the time of weaning, neuromuscular disease, chronic obstructive pulmonary disease receiving non-invasive ventilation, limitation of life support therapy during their admission, tracheostomized patients, spinal cord inj...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Medical and surgical ICU patients with 18 years of age or older
- • First episode of mechanical ventilation for more than 24 hours
- Exclusion Criteria:
- • Structural neurological disorder
- • Acute toxic-metabolic neurological encephalopathy with neurological deficit \[estimated by a Glasgow Coma Score (GCS) \<14 points\] at the time of weaning
- • Neuromuscular disease
- • Chronic obstructive pulmonary disease (COPD) receiving NIV
- • Limitation of life support therapy during their admission
- • Tracheostomized patients
- • Spinal cord injuries
- • Scheduled surgical procedure during the 48 hours following extubation
- • Intensive care unit readmission
- • Transfer to another centre
- • Contraindication to non-invasive mechanical ventilation
About Fundación Para El Fomento De La Investigación Sanitaria Y Biomédica De La Comunitat Valenciana
The Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana is a prominent clinical trial sponsor dedicated to advancing health research in the Valencian Community. By fostering collaboration between healthcare institutions, academic entities, and industry partners, the foundation aims to enhance biomedical innovation and improve public health outcomes. With a focus on prioritizing patient welfare and ethical research practices, it actively supports the development of cutting-edge therapies and medical solutions through rigorous clinical trials and research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Castellón De La Plana, Castello, Spain
Patients applied
Trial Officials
ALBERTO BELENGUER MUNCHARAZ
Principal Investigator
HOSPITAL GENERAL UNIVERSITARIO CASTELLON
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials